重组人血管内皮抑制素治疗非小细胞肺癌的疗效及对血清肿瘤标志物的影响  

Efficacy of recombinant human endostatin in the treatment of non-small cell lung cancer and its effect on serum tumor markers

作　　者：朱莹 郭云霞[2] 易善永 闫巧辉 吕朋举 ZHU Ying;GUO Yunxia;YI Shanyong;YAN Qiaohui;LYU Pengju(Department of Oncology,Zhengzhou Central Hospital Affiliated To Zhengzhou University,Zhengzhou 450007,He’nan,China;Department of Gastroenterology,People’s Hospital of Zhengzhou,Zhengzhou 450000,He’nan,China;Translational Medicine Center,Zhengzhou Central Hospital Affiliated To Zhengzhou University,Zhengzhou 450007,He’nan,China)

机构地区：[1]郑州大学附属郑州中心医院肿瘤内科,郑州450007 [2]郑州人民医院消化内科,郑州450000 [3]郑州大学附属郑州中心医院转化医学中心,郑州450007

出　　处：《癌症进展》2022年第20期2118-2121,共4页Oncology Progress

摘　　要：目的观察重组人血管内皮抑制素治疗非小细胞肺癌的临床疗效及对肿瘤标志物的影响。方法将110例非小细胞肺癌患者依照治疗方法的不同分为对照组与观察组,每组55例。对照组患者采用奈达铂联合多西他赛治疗,观察组患者在此基础上加入重组人血管内皮抑制素治疗。比较两组患者治疗前后的血清癌胚抗原(CEA)、鳞状细胞癌抗原(SCC-Ag)、血管内皮生长因子(VEGF)、用力肺活量(FVC)、第1秒用力呼气量(FEV_(1))及生活质量,同时对比两组患者的疗效。结果治疗后,观察组患者客观有效率高于对照组,差异有统计学意义(P﹤0.05)。治疗后,两组患者血清CEA、SCC-Ag及VEGF水平均明显低于本组治疗前,且观察组患者血清CEA、SCC-Ag及VEGF水平均明显低于对照组,差异均有统计学意义(P﹤0.01)。治疗后,两组患者FVC、FEV1均高于本组治疗前,且观察组患者FVC、FEV_(1)均高于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者肺癌患者生活质量评定量表(FACT-L)各维度评分均高于本组治疗前,且观察组患者FACT-L量表各维度评分均高于对照组,差异均有统计学意义(P﹤0.05)。结论重组人血管内皮抑制素治疗可有效降低非小细胞肺癌患者的血清肿瘤标志物水平,同时改善其肺功能和生活质量,提高客观有效率,可在临床中加以推广应用。Objective To observe the clinical efficacy of recombinant human endostatin in the treatment of non-small cell lung cancer and its impact on tumor markers.Method A total of 110 patients with non-small cell lung cancer were divided into control group and observation group according to different treatment methods,with 55 cases in each group.The patients in the control group were treated with nedaplatin combined with docetaxel,and the patients in the observation group were treated with recombinant human endostatin based on the control group.The serum carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC-Ag),vascular endothelial growth factor(VEGF),forced vital capacity(FVC),forced expiratory volume in first second(FEV_(1)),and quality of life were compared between the two groups before and after the treatment.At the same time,the therapeutic effects of the two groups were compared.Result After the treatment,the objective response rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of serum CEA,SCC-Ag,and VEGF in the two groups were significantly lower than those before the treatment,and the levels of these indicators in the observation group were significantly lower than those in the control group,and the differences were statistically significant(P<0.01).After the treatment,the FVC and FEV_(1) in the two groups were higher than those before the treatment,and the FVC and FEV1 in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the scores of each dimension of functional assessment of cancer therapy-lung(FACT-L)of patients in the two groups were higher than those before the treatment,and the scores of each dimension of FACT-L in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Recombinant human endostatin could effectivel

关 键 词：重组人血管内皮抑制素 非小细胞肺癌 肿瘤标志物 肺功能 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]